D-Dimer Plasma Levels Parallel the Clinical Response to Omalizumab in Patients with Severe Chronic Spontaneous Urticaria

2017 ◽  
Vol 172 (1) ◽  
pp. 40-44 ◽  
Author(s):  
Riccardo Asero ◽  
Angelo V. Marzano ◽  
Silvia Ferrucci ◽  
Massimo Cugno
Keyword(s):  
Clinical Response ◽  
Plasma Levels ◽  
Chronic Spontaneous Urticaria ◽  
D Dimer

Baseline D‐dimer plasma levels correlate with disease activity but not with the response to omalizumab in chronic spontaneous urticaria

Allergy ◽  
2019 ◽  
Vol 74 (12) ◽  
pp. 2538-2538 ◽  
Author(s):  
Riccardo Asero ◽  
Angelo V. Marzano ◽  
Silvia Ferrucci ◽  
Giovanni Genovese ◽  
Massimo Cugno
Keyword(s):  
Disease Activity ◽  
Plasma Levels ◽  
Chronic Spontaneous Urticaria ◽  
D Dimer

scholarly journals D-Dimer plasma levels in patients with coronary artery disease

2006 ◽  
Vol 28 (4) ◽  
Author(s):  
Luciana M. Lima ◽  
Marinez O. Sousa ◽  
Ana Paula Fernandes ◽  
Adriano P. Sabino ◽  
Cirilo P. Fonseca Neto ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Plasma Levels ◽  
Artery Disease ◽  
D Dimer

Elevated baseline D-dimer plasma levels are associated with a prompt response to omalizumab in patients with severe CSU

2017 ◽  
Vol 5 (6) ◽  
pp. 1740-1742 ◽  
Author(s):  
Riccardo Asero ◽  
Angelo Valerio Marzano ◽  
Silvia Ferrucci ◽  
Massimo Cugno
Keyword(s):  
Plasma Levels ◽  
D Dimer ◽  
Prompt Response

The relationships between clinical response, psychophysiological variables and plasma levels of amitriptyline and diazepam in neurotic outpatients

1981 ◽  
Vol 72 (3) ◽  
pp. 233-240 ◽  
Author(s):  
Eve C. Johnstone ◽  
Rachel C. Bourne ◽  
T. J. Crow ◽  
C. D. Frith ◽  
S. Gamble ◽  
...  
Keyword(s):  
Clinical Response ◽  
Plasma Levels

Abstract P663: Polygenic Risk Scores for Plasma Levels of Fibrin D-Dimer and Tissue Plasminogen Activator Are Associated With Non-Lacunar Stroke

Stroke ◽  
2021 ◽  
Vol 52 (Suppl_1) ◽  
Author(s):  
Yonit A Addissie ◽  
Brady Gaynor ◽  
Thomas Jaworek ◽  
Huichun Xu ◽  
Colin O Stine ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Plasma Levels ◽  
Early Onset ◽  
Late Onset ◽  
Plasma Concentrations ◽  
Risk Scores ◽  
Lacunar Stroke ◽  
Related Factors ◽  
Pai 1 ◽  
D Dimer

Introduction: Plasma concentrations of prothrombotic factors such as fibrinogen have previously been associated with ischemic stroke risk. To extend this observation, we examined the association of polygenic risk scores (PRS) for increased plasma levels of thrombosis-related factors with ischemic stroke. Our hypotheses were that these PRS would be more associated with early than late onset stroke and with non-lacunar than lacunar stroke. Methods: We identified 9053 late onset (≥ 60 years) stroke cases from the NINDS International Stroke Genetics Consortium (SiGN) with 24804 controls and 6594 early onset (< 60 years) stroke cases from the Genetics of Early Onset Ischemic Stroke Consortium with 30561 controls. We identified previously known loci associated with plasma levels of four thrombosis-related factors: fibrinogen, fibrin D-dimer, tPA and PAI-1 from prior GWAS studies and developed genome-wide PRS for plasma concentrations of these factors. We then used logistic regression to test the association of these scores with risk of stroke and stroke subtype. Results: PRS for fibrin D dimer levels were associated with increased risk for all stroke and specifically for older (p = 0.019), but not younger (p = 0.22) onset stroke. PRS for tPA levels were also marginally associated with older (p = 0.06), but not younger (p = 0.24) onset stroke. Genetic risk scores for both D dimer and tPA were associated with non-lacunar stroke (Table 1). Further analyses stratified by age revealed PRS for D dimer to be significantly associated with non-lacunar stroke (but not lacunar stroke) in both late and early onset cohorts. PRS for fibrinogen and PAI-1 were not associated with stroke. Conclusion: Genomic risk scores for thrombosis-related factors including D dimer and tPA levels were associated with risk for ischemic stroke, and specifically, non-lacunar stroke.

PLASMA LEVELS OF FRAGMENT D-DIMER OF CROSSLINKED FIBRIN DURING THROMBOLYTIC THERAPY WITH RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR

1987 ◽  
Author(s):  
P Declerck ◽  
P Mombaerts ◽  
P Holvoet ◽  
D Collen
Keyword(s):  
Thrombolytic Therapy ◽  
Plasma Levels ◽  
Degradation Products ◽  
Fibrin Clot ◽  
Tissue Type ◽  
Fibrin Degradation Products ◽  
Type Plasminogen Activator ◽  
Rate Of Increase ◽  
Significant Difference ◽  
D Dimer

Plasma levels of crosslinked fibrin degradation products (XLDP) were measured before and at the end of the administration of rt-PA (40 to 100 mg over 1.5 to 8 hours) in healthy volunteers (n=5) and patients with deep venous thrombosis (DVT) (n=8), pulmonary embolism (PE) (n=16)and myocardial infarction(MI)(n=10). Determinations were performed using our newly developed ELISA, specific for crosslinked fibrin derivatives, based on two monoclonal antibodies (15C5 and 8D3H2) raised against purified human fragment D-dimer. All plasma samples were collected on citrate and trasylol. Results are expressed as mean and range of D-dimer equivalents (μg/ml).Baseline levels in patients with MI are only slightly elevated. The increased levels inDVT and PE are in agreement with previous studies. After infusion of rt-PA a small increase of XLDP is seen even innormal subjects. A very marked increasof XLDP is detected in patients with PE and DVT but not in patients with MI. This may reflect differences in the amounts of fibrin clot dissolved in these patient groups.No significant correlation was found between the increase of XLDP and success of therapy, although a significant difference in D-dimer levels was formed between the two groups with PE: successful (n=ll): 116 (range 61-192) vs. unsuccessful (n=5): 68 (36-155).Thus, XLDP are already elevated under baseline conditions in patients with DVT and PE and increase very markedly during thrombolytic therapy. The absolute levels after thrombolytic therapy do not strictly correlate with success of therapy. It could be useful to measure D-dimer levels during early stages of therapy, because the rate of increase of XLDP levels might correlate with the efficacy of thrombolytic treatment.

Sign in / Sign up

Export Citation Format

Share Document